Nifty
:
22620.40
Sensex
:
73730.16
50.05 (0.22%)
-609.28 (-0.82%)
Nifty
Sensex
:
:
22620.40
73730.16
50.05 (0.22%)
-609.28 (-0.82%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 500257 | NSE: LUPIN

NSE BSE
1615.95
26-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1590.00
  •  1624.00
  •  1585.10
  •  1594.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  587789
  •  9489.87
  •  1704.25
  •  680.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 73,642.38
  • 40.44
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 75,543.27
  • 0.25%
  • 5.23

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.01%
  • 0.39%
  • 5.70%
  • FII
  • DII
  • Others
  • 18.29%
  • 26.78%
  • 1.83%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.96
  • -0.13
  • 3.15

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.42
  • -8.41
  • -7.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -13.51
  • -6.80
  • -29.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.07
  • 27.18
  • 40.21

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.46
  • 3.22
  • 3.37

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.70
  • 16.50
  • 17.42

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
5,197.41
4,322.22
20.25%
5,038.56
4,145.52
21.54%
4,814.06
3,743.84
28.59%
4,430.08
3,883.03
14.09%
Expenses
4,175.45
3,806.18
9.70%
4,120.80
3,692.53
11.60%
3,957.77
3,511.52
12.71%
3,852.31
3,615.21
6.56%
EBITDA
1,021.96
516.04
98.04%
917.76
452.99
102.60%
856.29
232.32
268.58%
577.77
267.82
115.73%
EBIDTM
19.66%
11.94%
18.21%
10.93%
17.79%
6.21%
13.04%
6.90%
Other Income
45.35
34.59
31.11%
40.40
14.94
170.41%
22.83
5.56
310.61%
37.27
15.68
137.69%
Interest
74.01
84.09
-11.99%
80.64
54.88
46.94%
85.67
42.78
100.26%
92.55
41.47
123.17%
Depreciation
257.20
220.40
16.70%
247.85
203.47
21.81%
234.66
192.83
21.69%
263.99
327.19
-19.32%
PBT
736.10
246.14
199.06%
629.67
209.58
200.44%
558.79
2.27
24,516.30%
258.50
-85.16
-
Tax
117.40
88.49
32.67%
134.35
75.11
78.87%
105.46
89.09
18.37%
16.11
426.73
-96.22%
PAT
618.70
157.65
292.45%
495.32
134.47
268.35%
453.33
-86.82
-
242.39
-511.89
-
PATM
11.90%
3.65%
9.83%
3.24%
9.42%
-2.32%
5.47%
-13.18%
EPS
13.46
3.37
299.41%
10.76
2.85
277.54%
9.94
-1.96
-
5.19
-11.40
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
19,480.11
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
Net Sales Growth
21.03%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
 
Cost Of Goods Sold
6,819.67
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
Gross Profit
12,660.44
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
GP Margin
64.99%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
Total Expenditure
16,106.33
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
Power & Fuel Cost
-
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
% Of Sales
-
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
Employee Cost
-
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
% Of Sales
-
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
Manufacturing Exp.
-
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
% Of Sales
-
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
General & Admin Exp.
-
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
% Of Sales
-
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
Selling & Distn. Exp.
-
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
% Of Sales
-
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
Miscellaneous Exp.
-
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
775.26
% Of Sales
-
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
EBITDA
3,373.78
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
EBITDA Margin
17.32%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
Other Income
145.85
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
Interest
332.87
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
Depreciation
1,003.70
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
PBT
2,183.06
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
Tax
373.32
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
Tax Rate
17.10%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
PAT
1,809.74
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
PAT before Minority Interest
1,791.01
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
Minority Interest
-18.73
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
PAT Margin
9.29%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
PAT Growth
690.28%
-
-
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
 
EPS
39.71
9.44
-33.53
26.67
-6.01
13.42
5.44
55.94
49.50
52.74
40.30

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
Share Capital
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
Total Reserves
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
Non-Current Liabilities
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
Secured Loans
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
Unsecured Loans
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
Long Term Provisions
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
Current Liabilities
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
Trade Payables
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
Other Current Liabilities
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
Short Term Borrowings
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
Short Term Provisions
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
Total Liabilities
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
Net Block
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
Gross Block
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
Accumulated Depreciation
9,698.33
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
Non Current Assets
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
Capital Work in Progress
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
Non Current Investment
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
Long Term Loans & Adv.
622.28
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
Other Non Current Assets
56.34
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
Current Assets
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
Current Investments
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
Inventories
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
Sundry Debtors
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
Cash & Bank
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
Other Current Assets
1,745.94
497.54
556.89
537.33
1,769.95
1,711.95
1,191.01
1,241.22
534.98
532.99
Short Term Loans & Adv.
1,077.50
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
Net Current Assets
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
Total Assets
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
PBT
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
Adjustment
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
Changes in Working Capital
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
Cash after chg. in Working capital
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
Net Fixed Assets
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
Net Investments
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
Others
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
Cash from Financing Activity
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
Net Cash Inflow / Outflow
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
Opening Cash & Equivalents
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
Closing Cash & Equivalent
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
ROA
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
ROE
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
ROCE
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
Fixed Asset Turnover
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
Receivable days
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
Inventory Days
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
Payable days
141.88
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
63.78
Cash Conversion Cycle
-27.27
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
76.37
Total Debt/Equity
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
Interest Cover
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Lupin gets EIR for Aurangabad manufacturing facility
    24th Apr 2024, 09:27 AM

    The inspection was conducted from March 6 to March 15, 2024

    Read More
  • USFDA completes GMP inspection at Lupin’s API manufacturing facility at Dabhasa
    12th Apr 2024, 16:00 PM

    The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

    Read More
  • Lupin recalls 26,352 bottles of Rifampin Capsules in US market
    10th Apr 2024, 16:38 PM

    As per the US Food and Drug Administration, the company is recalling the lot for being ‘Subpotent’

    Read More
  • Lupin launches first generic version of Oracea in United States
    10th Apr 2024, 09:17 AM

    Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions of rosacea in adult patients

    Read More
  • Lupin receives USFDA’s approval for Valbenazine Capsules
    9th Apr 2024, 12:45 PM

    Valbenazine Capsules, 40 mg and 80 mg had estimated annual sales of $1,621 million in the US

    Read More
  • Lupin gets nod to transfer trade generics business in India to Lupin Life Sciences
    23rd Mar 2024, 11:15 AM

    The Board of Directors of the company, at its meeting held on March 22, 2024, has approved the same

    Read More
  • Lupin receives USFDA’s approval for Minzoya tablets
    16th Feb 2024, 14:41 PM

    The product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin launches Ganirelix Acetate Injection
    15th Feb 2024, 14:05 PM

    Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S.

    Read More
  • Lupin launches Bromfenac Ophthalmic Solution
    13th Feb 2024, 16:30 PM

    Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries

    Read More
  • Lupin reports around 4-fold jump in Q3 consolidated net profit
    8th Feb 2024, 11:20 AM

    Consolidated total income of the company increased by 20.43% at Rs 5,226.78 crore for Q3FY24

    Read More
  • Lupin - Quarterly Results
    7th Feb 2024, 19:39 PM

    Read More
  • Lupin receives USFDA’s approval for Bromfenac Ophthalmic Solution
    7th Feb 2024, 11:19 AM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin receives USFDA’s approval for Dronedarone Tablets
    1st Feb 2024, 15:40 PM

    The product will be manufactured at Lupin’s Goa facility in India

    Read More
  • Lupin gets tentative nod for Rivaroxaban Tablets
    24th Jan 2024, 10:08 AM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin gets USFDA’s nod for Febuxostat Tablets
    18th Jan 2024, 17:34 PM

    The product will be manufactured at Lupin’s Pithampur facility in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.